BTAX.US Biostax Corp.

Healthcare Biotechnology USA Stocks
0.0002 USD
Close of Oct 5, 2026
0.0001 0.0002
Market cap
USD 15.7K
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 4 quarters up to Mar 2025.

Is BTAX.US undervalued?

Graham number

The Graham number of Biostax Corp. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Biostax Corp. fundamental analysis

No fundamental analysis for Biostax Corp. yet.

Biostax Corp. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Biostax Corp.

Biostax Corp. operates as a biopharmaceutical company that acquires, develops, and commercializes pharmaceutical and biotechnology products. Its lead investigational drug candidate Lodonal, an once-a-day immune system regulator for the management of human immunodeficiency virus and acquired immune deficiency syndrome (HIV/AIDS). Its programs also include Global Telehealth platform; Medtech asset, an early development stage program that uses blockchain and smart contracts to …

Full company profile